CELZ: מכפיל P/S Creative Medical Technology
Creative Medical Technology (CELZ) management is facing a liquidity shortage due to clinical trial expenses. The historical P/S level visualizes the consequences of this pressure, where the 849.40 mark indicates the current state. Creative Medical Technology (CELZ) monetizes urology patents by creating unique AmnioStem cellular products to combat male infertility, allowing the company to occupy vacant niches in regenerative medicine.
פילוחים אנליטיים של חברת Creative Medical Technology (CELZ)
The P/S ratio is calculated as the ratio of market capitalization to total sales, measuring the value of one dollar of revenue in the eyes of investors. For Creative Medical Technology (CELZ), with its pristine image in the StemSpine and Stem cell therapy sectors, the median P/S serves as a filter for market noise, allowing for the determination of the fair value of assets relative to the business's actual earnings.
